BlackRock Health Sciences Term Trust (NYSE:BMEZ) Plans $0.18 Monthly Dividend

Posted by Don Miller on Nov 13th, 2024

BlackRock Health Sciences Term Trust (NYSE:BMEZ – Get Free Report) announced a monthly dividend on Friday, November 1st,NASDAQ Dividends reports. Stockholders of record on Friday, November 15th will be given a dividend of 0.1769 per share on Friday, November 29th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 13.50%. The ex-dividend date is Friday, November 15th.

BlackRock Health Sciences Term Trust has raised its dividend payment by an average of 20.7% annually over the last three years.

BlackRock Health Sciences Term Trust Trading Down 0.7 %

NYSE:BMEZ traded down 0.11 during midday trading on Wednesday, reaching 15.73. 143,702 shares of the stock traded hands, compared to its average volume of 264,060. BlackRock Health Sciences Term Trust has a 12-month low of 13.41 and a 12-month high of 16.59. The business has a 50-day moving average of 15.80 and a two-hundred day moving average of 15.56.

Insider Activity

In other BlackRock Health Sciences Term Trust news, major shareholder Saba Capital Management, L.P. bought 1,633 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The shares were purchased at an average cost of 15.89 per share, for a total transaction of 25,948.37. Following the purchase, the insider now directly owns 20,653,378 shares in the company, valued at 328,182,176.42. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders acquired 99,630 shares of company stock worth $1,585,113.

BlackRock Health Sciences Term Trust Company Profile

(Get Free Report)

BlackRock Health Sciences Trust II’s (BMEZ) (the ‘Trust’) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries.